Welcome to START’s Virtual Panel Series
Explore the forefront of oncology research with our series, "The Power of Community Site Networks: Advancing Science & Broadening Access to Early Phase Cancer Trials." This series brings together leading experts from around the world to discuss the latest advancements in community-based clinical trials and their impact on patient care.
About the Series
Our Virtual Panel Series is designed to dive deep into critical topics within oncology, focusing on how community-based trials are revolutionizing cancer research and treatment.
START invites all stakeholders involved in the drug development process—including sponsors, oncologists, regulatory bodies, and patients—to participate in these engaging sessions. The Virtual Panel Series offers a unique opportunity to explore how community site networks are reshaping the landscape of early-phase cancer trials.
Register today for our upcoming sessions!
Antibody-Drug Conjugates (ADCs):
Targeted Therapeutics in the Modern Age
ADCs represent a significant advancement in oncology, combining the targeting ability of antibodies with the potent cell-killing capacity of cytotoxic drugs. This session will dive into the latest advancements, challenges, and strategies for optimizing ADC clinical trials.
Date: September 25, 2024
Time: 10:00am ET (45 min. session)
Meet the Speakers:
-
Justin A. Call, MD, Director of Clinical Research at START Mountain Region
-
Austin Duffy, MB, BCh, MRCPI, DMed, Director of Clinical Research at START Dublin
-
David Quinn, MD, Executive Medical Director at AbbVie
-
Manish R. Sharma, MD, Co-Director of Clinical Research at START Midwest
Bispecific Antibodies Uncovered:
Dual Targeting Strategies in Cancer Research
Bispecific antibodies are next-generation therapies designed to engage multiple pathways or cellular interactions simultaneously. As these innovative treatments gain traction, the challenges and opportunities in conducting these types of clinical trials are becoming increasingly complex.
Date: November 6, 2024
Time: 10:00am ET (45 min. session)
Meet the Speakers:
-
André Mansinho, MD, MSc, Director of Clinical Research at START Lisbon
-
Drew W. Rasco, MD, Associate Director of Clinical Research at START San Antonio
- William B. McKean, MD, PhD, Clinical Investigator at START Mountain Region
Malignant Hematology:
Advancing Treatment in Blood Cancers
This session will cover groundbreaking research, unique challenges, and innovative strategies for clinical trials in malignant hematology. Our expert panelists will share their insights and experiences, highlighting the importance of community-based trials in bringing novel therapies to patients.
Date: November 13, 2024
Time: 10:00am ET (45 min. session)
Meet the Speakers:
-
Daniel Morillo, MD, Clinical Investigator & Hematologist at START Madrid-FJD
-
Andrew Sochacki, MD, Clinical Investigator & Hematologist at START Midwest
-
Gala Vega, MD, Clinical Investigator & Hematologist at START Madrid-FJD
Precision Oncology:
Tailoring Treatments for Better Patient Outcomes
Precision oncology represents a significant shift towards personalized cancer treatment, enabling therapies tailored to the unique genetic makeup of each patient’s tumor. This session will focus on how molecular profiling and targeted therapies are revolutionizing patient care, optimizing clinical trial design, and improving outcomes.
Date: December 4, 2024
Time: 10:00am ET (45 min. session)
Meet the Speakers:
-
Nehal J. Lakhani, MD, PhD, Co-Director of Clinical Research at START Midwest
-
Geraldine O'Sullivan-Coyne, MD, MRCPI, PhD, Clinical Investigator at START Dublin
-
Kyriakos P. Papadopoulos, MD, Co-Director of Clinical Research at START San Antonio